Collectively, our findings reveal a novel mechanism underlying the anti-steatosis effect of Andro by suppressing FATP2-mediated fatty acid uptake, suggesting the potential therapeutic application of Andro in the treatment of NAFLD. The gene discussed is SLC27A2; the disease is metabolic dysfunction-associated steatotic liver disease.